Casey C May1, Shaily Arora1, Sara E Parli1, Justin F Fraser2, Melissa Thompson Bastin1, Aaron M Cook3,4. 1. Department of Pharmacy, University of Kentucky HealthCare, 800 Rose Street Room H110, Lexington, KY, 40536, USA. 2. Department of Neurological Surgery, University of Kentucky HealthCare, 800 Rose Street MS108A, Lexington, KY, 40536, USA. 3. Department of Pharmacy, University of Kentucky HealthCare, 800 Rose Street Room H110, Lexington, KY, 40536, USA. amcook0@email.uky.edu. 4. Department of Pharmacy Practice & Science, University of Kentucky College of Pharmacy, 798 South Limestone Street, Lexington, KY, 40536, USA. amcook0@email.uky.edu.
Abstract
BACKGROUND: Patients with subarachnoid hemorrhage (SAH) typically exhibit hyperdynamic cardiovascular hemodynamics, which may lead to increased medication clearance. The aims of this study were to evaluate the actual creatinine clearance (CrClA) in an aneurysmal SAH population and the effect of the development of cerebral vasospasm (CV) along with its treatment to better understand if this population exhibits augmented renal clearance (ARC). METHODS: This was a prospective, single-center study in a neurosciences ICU at a university hospital. A total of 20 patients were consented and provided a 24-h urine sample to measure the CrClA. If patients experienced CV, a 24-h urine collection was repeated during vasospasm treatment. CrClA was measured using a modified Jaffe assay. RESULTS: Among the 20 patients enrolled, the mean SAH CrClA was 325.93 ± 135.20 ml/min 1.73 m(2) and this differed significantly from the SAH estimated creatinine clearance (CrClE) 144.93 ± 42.82 ml/min 1.73 m(2) (p < 0.001). Four patients developed CV; the mean CV CrClA was 558.43 ± 356.12 ml/min 1.73 m(2) and there was no significant difference when compared to those patients' mean SAH CrClA (246.91 ± 84.14 ml/min 1.73 m(2), p = 0.16). CONCLUSIONS: ARC was present in 100 % of the patients with recent SAH enrolled. Although ARC remained present in the patients who experienced CV, their creatinine clearance was not significantly further augmented. Further work is needed to clarify the impact of such clearances on renally excreted medications and how the development and treatment of CV further augment these findings.
BACKGROUND:Patients with subarachnoid hemorrhage (SAH) typically exhibit hyperdynamic cardiovascular hemodynamics, which may lead to increased medication clearance. The aims of this study were to evaluate the actual creatinine clearance (CrClA) in an aneurysmalSAH population and the effect of the development of cerebral vasospasm (CV) along with its treatment to better understand if this population exhibits augmented renal clearance (ARC). METHODS: This was a prospective, single-center study in a neurosciences ICU at a university hospital. A total of 20 patients were consented and provided a 24-h urine sample to measure the CrClA. If patients experienced CV, a 24-h urine collection was repeated during vasospasm treatment. CrClA was measured using a modified Jaffe assay. RESULTS: Among the 20 patients enrolled, the mean SAHCrClA was 325.93 ± 135.20 ml/min 1.73 m(2) and this differed significantly from the SAH estimated creatinine clearance (CrClE) 144.93 ± 42.82 ml/min 1.73 m(2) (p < 0.001). Four patients developed CV; the mean CV CrClA was 558.43 ± 356.12 ml/min 1.73 m(2) and there was no significant difference when compared to those patients' mean SAHCrClA (246.91 ± 84.14 ml/min 1.73 m(2), p = 0.16). CONCLUSIONS: ARC was present in 100 % of the patients with recent SAH enrolled. Although ARC remained present in the patients who experienced CV, their creatinine clearance was not significantly further augmented. Further work is needed to clarify the impact of such clearances on renally excreted medications and how the development and treatment of CV further augment these findings.
Authors: Andrew A Udy; Julie M Varghese; Mahdi Altukroni; Scott Briscoe; Brett C McWhinney; Jacobus P Ungerer; Jeffrey Lipman; Jason A Roberts Journal: Chest Date: 2012-07 Impact factor: 9.410
Authors: E Sander Connolly; Alejandro A Rabinstein; J Ricardo Carhuapoma; Colin P Derdeyn; Jacques Dion; Randall T Higashida; Brian L Hoh; Catherine J Kirkness; Andrew M Naidech; Christopher S Ogilvy; Aman B Patel; B Gregory Thompson; Paul Vespa Journal: Stroke Date: 2012-05-03 Impact factor: 7.914
Authors: Mohammad H Alshaer; Brooke Barlow; Nicole Maranchick; Miriam Moser; Leon Gramss; Heinz Burgmann; Valentin Al Jalali; Michael Wölfl-Duchek; Walter Jäger; Stefan Poschner; Walter Plöchl; Andrea Reinprecht; Karl Rössler; Andreas Gruber; Markus Zeitlinger; Charles A Peloquin; Arthur Hosmann Journal: Antimicrob Agents Chemother Date: 2022-07-14 Impact factor: 5.938
Authors: Kathryn A Morbitzer; J Dedrick Jordan; Kelly A Sullivan; Emily A Durr; Casey M Olm-Shipman; Denise H Rhoney Journal: Neurocrit Care Date: 2016-10 Impact factor: 3.210
Authors: Evelyn Dhont; Tatjana Van Der Heggen; Annick De Jaeger; Johan Vande Walle; Peter De Paepe; Pieter A De Cock Journal: Pediatr Nephrol Date: 2018-10-29 Impact factor: 3.714
Authors: Idoia Bilbao-Meseguer; Helena Barrasa; Alicia Rodríguez-Gascón; Eduardo Asín-Prieto; Javier Maynar; José Ángel Sánchez-Izquierdo; María Ángeles Solinís; Arantxazu Isla Journal: J Intensive Care Date: 2022-04-21